Neurogene Inc. (NGNE) insider buying and SEC filings
Neurogene Inc. · CIK 1404644
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- Dec 31
- Former names
- Neoleukin Therapeutics, Inc.; AQUINOX PHARMACEUTICALS, INC; AQUINOX PHARMACEUTICALS (USA) INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$1.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 6–7, 2026 | Planned (10b5-1) | Christine Mikail Cvijic (CFO and Director) sold 4,800 shares between Jul 6 and Jul 7 at about $36.12 ($173K), marked as a 10b5-1 plan trade. Holdings down 5% to 84,040 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 1–2, 2026 | Planned (10b5-1) | Christine Mikail Cvijic (CFO and Director) sold 4,800 shares between Jul 1 and Jul 2 at about $34.71 ($167K), marked as a 10b5-1 plan trade. Holdings down 5% to 88,840 shares. | SEC filing Filed Jul 2, 2026 |
| May 6, 2026 | Planned (10b5-1) | Christine Mikail Cvijic (CFO and Director) sold 9,600 shares at about $31.26 ($300K), marked as a 10b5-1 plan trade. Holdings down 9% to 93,640 shares. | SEC filing Filed May 8, 2026 |
| Mar 26, 2026 | Planned (10b5-1) | Julie Jordan (Chief Medical Officer) sold 828 shares at about $21.89 ($18K), marked as a 10b5-1 plan trade. Holdings down 6% to 12,472 shares. | SEC filing Filed Mar 30, 2026 |
| Mar 26, 2026 | Planned (10b5-1) | Rachel McMinn (CEO and Director) sold 3,352 shares at about $22.07 ($74K), marked as a 10b5-1 plan trade. Holdings down <1% to 1,344,307 shares. | SEC filing Filed Mar 30, 2026 |
| Mar 26, 2026 | Planned (10b5-1) | Christine Mikail Cvijic (CFO) sold 2,558 shares at about $21.62 ($55K), marked as a 10b5-1 plan trade. Holdings down 2% to 103,240 shares. | SEC filing Filed Mar 30, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Stuart Cobb (Chief Scientific Officer) sold 6,797 shares at about $20.81 ($141K), marked as a 10b5-1 plan trade. Holdings down 18% to 30,497 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Christine Mikail Cvijic (CFO) sold 4,045 shares at about $20.81 ($84K), marked as a 10b5-1 plan trade. Holdings down 4% to 105,798 shares. | SEC filing Filed Mar 17, 2026 |
| Feb 27, 2026 | Planned (10b5-1) | Christine Mikail Cvijic (CFO) sold 4,800 shares at about $25.11 ($121K), marked as a 10b5-1 plan trade. Holdings down 4% to 109,843 shares. | SEC filing Filed Mar 3, 2026 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NGNE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.